Scotland backs saxagliptin for type-2 diabetes

People in Scotland with type-2 diabetes now have access to a wider choice of treatments after saxagliptin (Onglyza) was accepted for use within NHS Scotland.

The Scottish Medicine Consortium (SMC) approved restricted use of the drug in adult patients with type-2 diabetes as an add-on combination therapy with metformin, when metformin plus exercise does not achieve adequate glycaemic control.

The dipeptidyl peptidase-4 inhibitor is restricted to use when the addition of sulphonylureas is not appropriate, and represents an alternative to other agents such as thiazolidinediones, said the SMC.

Efficacy, as assessed by lowering of HbA1c, is comparable to other dipeptidyl peptidase-4 inhibitors and the drug appeared to have minimal effect on body weight, it added.

Saxagliptin is also licensed for use in combination with sulphonylureas or thiazolidinedione drugs for the treatment of type-2 diabetes. The manufacturer's submission related only to the use of saxagliptin in combination with metformin. 

However, the SMC said it cannot recommend the use of saxagliptin in combination with sulphonylureas or thiazolidinediones.

Manufacturer Bristol-Myers Squibb estimated that 4,576 patients would be eligible for add-on treatment with a thiazolidinedione or DPP-IV inhibitor.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Subject access requests to GP practices increased by a third under GDPR

Subject access requests to GP practices increased by a third under GDPR

The number of subject access requests (SARs) GP practices receive each month has...

RCGP criticises GP at Hand video showing antibiotics prescribed for sore throat

RCGP criticises GP at Hand video showing antibiotics prescribed for sore throat

A promotional video for Babylon GP at Hand that shows a patient with a sore throat...

Review into overprescribing aims to give GPs power to challenge hospital scrips

Review into overprescribing aims to give GPs power to challenge hospital scrips

A government review of overprescribing in the NHS could see GPs given more power...

Submit your session ideas for the RCGP Annual Conference 2019

Submit your session ideas for the RCGP Annual Conference 2019

GPs can now submit ideas for sessions at the RCGP Annual Conference in Liverpool,...

Scottish GP workforce increases for first time in 10 years, figures show

Scottish GP workforce increases for first time in 10 years, figures show

GP numbers in Scotland have risen slightly for the first time in 10 years despite...

More than 16m GP practice appointments a year lost to DNAs

More than 16m GP practice appointments a year lost to DNAs

More than 16m appointments at GP practices are lost every year because patients fail...